TransMedics Group, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Waleed H. Hassanein
- Full Time Employees
- 898
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 200 Minuteman Road Andover MA United States 01810
- IPO Date
- May 2, 2019
- CIK
- 0001756262
- Website
- transmedics.com
- Similar Companies
- Business
- TransMedics Group, Inc. develops and commercializes medical technologies that transform organ transplant therapy for patients with end-stage heart, lung and liver failure; the company offers the Organ Care System (OCS), a portable extracorporeal warm perfusion, optimization and monitoring platform that replicates near-physiologic conditions for donor organs outside the body, with specific systems for hearts, lungs and livers; it also provides the National OCS Program (NOP), an end-to-end outsourced solution encompassing organ procurement, OCS perfusion management, transplant logistics and aviation transportation services, supported by trained surgeons, clinical specialists and coordinators. TransMedics operates primarily in the United States, with international reach, and targets transplant centers serving patients with end-stage organ failure. Founded in 1998 and headquartered in Andover, Massachusetts, the company continues to expand its capabilities through recent aircraft fleet acquisitions, including a fixed-wing plane purchased in January 2025 for $14.1 million from RCS Leasing, LLC, bringing its total to 20 aircraft as part of the NOP to enhance donor organ transportation.
Company News
TransMedics: 3 Key Takeaways for Long-Term Investors
TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?
TransMedics (TMDX) Recently Broke Out Above the 50-Day Moving Average
TransMedics Group Q3 Earnings Call Highlights
Unusual Options Volume Report: 3 Stocks Moving After Earnings
TransMedics (TMDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
TransMedics Group, Inc. (TMDX) Q3 2026 Earnings Call Transcript
TransMedics (TMDX) Q3 Earnings and Revenues Surpass Estimates
TransMedics Reports Third Quarter 2026 Financial Results
Reasons to Retain TransMedics Stock in Your Portfolio for Now
What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics to Present at Upcoming Investor Conferences
TransMedics selects Gogo Galileo HDX for nationwide organ transport fleet
TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
A Look at TransMedics Group Inc (TMDX) After 3.1% Decline -- GF Value $160.75 vs Price $72.40
Critical Review: TransMedics Group (NASDAQ:TMDX) & iRhythm Technologies (NASDAQ:IRTC)
TransMedics Group Inc (TMDX) Shares Fall 5.8% -- What GF Score of 74 Tells Investors
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?